Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $214,914 - $286,356
-4,200 Reduced 26.25%
11,800 $637,000
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $188,077 - $276,272
-3,100 Reduced 16.23%
16,000 $1.09 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $351,442 - $656,838
9,100 Added 91.0%
19,100 $1.2 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $43,470 - $67,770
-1,000 Reduced 9.09%
10,000 $561,000
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $848,700 - $1.16 Million
-20,700 Reduced 65.3%
11,000 $497,000
Q4 2022

Feb 14, 2023

SELL
$39.19 - $65.67 $11,757 - $19,701
-300 Reduced 0.94%
31,700 $1.29 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $1.96 Million - $2.68 Million
32,000 New
32,000 $2.09 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.05B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.